A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
出版年份 2014 全文链接
标题
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
作者
关键词
Ipilimumab, Vaccine, PROSTVAC, T cells, NK cells, Immunotherapy
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 63, Issue 4, Pages 407-418
出版商
Springer Nature
发表日期
2014-02-10
DOI
10.1007/s00262-014-1524-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- (2012) L. C. Ndhlovu et al. BLOOD
- Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
- (2012) M. K. Gleason et al. BLOOD
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tim-3-Expressing CD4+ and CD8+ T Cells in Human Tuberculosis (TB) Exhibit Polarized Effector Memory Phenotypes and Stronger Anti-TB Effector Functions
- (2012) Yueqin Qiu et al. PLoS Pathogens
- Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
- (2011) Mary L. Disis CANCER IMMUNOLOGY IMMUNOTHERAPY
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients
- (2011) Nicola Hardwick et al. Immunotherapy
- Myeloid derived suppressor cells in human diseases
- (2011) Tim F. Greten et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CD56brightCD16+ NK Cells: A Functional Intermediate Stage of NK Cell Differentiation
- (2011) V. Beziat et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective Effector Memory CD4 T Cells Depend on ICOS for Survival
- (2011) Tamson V. Moore et al. PLoS One
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination
- (2010) Matteo Vergati et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
- (2010) H.-T. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Does PSADT After Radical Prostatectomy Correlate With Overall Survival?—A Report From the SEARCH Database Group
- (2010) Anna E. Teeter et al. UROLOGY
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
- (2009) James L. Gulley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment
- (2009) M. L. Disis CLINICAL CANCER RESEARCH
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
- (2009) Hong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunosuppressive CD14+HLA-DRlow/−monocytes in prostate cancer
- (2009) Stanimir Vuk-Pavlović et al. PROSTATE
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
- (2008) K. S. Sfanos et al. CLINICAL CANCER RESEARCH
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started